目的：探讨HAD方案诱导治疗急性髓系白血病临床疗效及不良反应。方法将58例急性髓系白血病患者随机分为2组，治疗组30人，应用HAD方案诱导治疗，对照组28人随机应用DA/HA方案诱导治疗。结果 HAD组诱导化疗完全缓解率（CR）为76.7%，部分缓解率（PR）为13.3%，总有效率为90%，DA/HA方案诱导化疗完全缓解率（CR）为32.1%，部分缓解率（PR）为28.6%，总有效率为60.7%，观察组的缓解率及总有效率明显高于对照组，P＜0.05，差异有统计学意义，2组不良反应相当。HAD方案骨髓抑制及粒细胞缺乏严重程度相对DA/HA重一些。结论 HAD方案诱导化疗治疗急性髓系白血病疗效优于DA/HA方案，且毒副作用相当。%Objective Study clinical efficacy and adverse drug reaction of HAD regimen for acute myeloid leukemia. Methods 58 cases of acute myeloid leukemia patients were randomly divided into 2 groups, the treatment group of 30 patients were treated with HAD regimen, 28 cases in the control groups were treated with DA/HA group induction therapy. Results HAD group of induction chemotherapy complete remission (CR) rate was 76.7%, partial remission (PR) rate was 13.3%, the total effective rate was 90%. Complete remission induction chemotherapy of DA/HA regimen (CR) rate was 32.1%, partial remission (PR) rate was 28.6%, the total effective rate was 60.7%, relief and the rate of the observation group was better than that in control group, P<0.05. The difference was statistically signiifcant, adverse reaction in 2 groups were considerable. The HAD scheme of bone marrow suppression and agranulocytosis severity DA/HA were relatively heavier. Conclusion Take HAD regimen as induction chemotherapy in the treatment of acute myeloid leukemia curative effect is better than the DA/HA scheme, and has considerable side effects.
展开▼
